Evidence map›Paper›PMID 32095654›Full record

ArticleHeliyon2020

Classification of clear cell renal cell carcinoma based on

Xiangyu Li, Beste Turanli, Kajetan Juszczak, Woonghee Kim, Muhammad Arif, Yusuke Sato, Seishi Ogawa, Hasan Turkez, Jens Nielsen, Jan Boren and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Anti-Viral Activity of Conessine Against Influenza A Virus.International journal of molecular sciences · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Xiangyu LiScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Beste TuranliDepartment of Bioengineering, Istanbul Medeniyet University, Istanbul, Turkey.
Kajetan JuszczakScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Woonghee KimScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Muhammad ArifScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Yusuke SatoDepartment of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
Hasan TurkezDepartment of Molecular Biology and Genetics, Erzurum Technical University, Erzurum, 25240, Turkey.
Jens NielsenDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Jan BorenDepartment of Molecular and Clinical Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
Mathias UhlenScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Cheng ZhangScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Adil MardinogluScience for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Science for Life Laboratory · SEKyoto University · JPChalmers University of Technology · SEErzurum Technical University · TRIstanbul Medeniyet University · TRKing's College London · GBSahlgrenska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients and design effective treatment strategies. Here, we analyzed the survival outcome of ccRCC patients as a consequence of the differential expression of four transcript isoforms of the pyruvate kinase muscle type (

Indexed as

Alternative splicingBioinformaticsBiomarkerCancer researchDrug repositioningPKMSystems biologyTranscriptomics

Identifiers

PMID32095654
PMCPMC7033363
OpenAlexW3008441196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.